GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Market Cap

Regeneron Pharmaceuticals (WBO:REGN) Market Cap : €76,733 Mil (As of Dec. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Regeneron Pharmaceuticals's share price for the quarter that ended in Sep. 2024 was €947.6. Regeneron Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 110 Mil. Therefore, Regeneron Pharmaceuticals's market cap for the quarter that ended in Sep. 2024 was €104,347 Mil.

Regeneron Pharmaceuticals's quarterly market cap increased from Mar. 2024 (€98,286 Mil) to Jun. 2024 (€107,651 Mil) but then declined from Jun. 2024 (€107,651 Mil) to Sep. 2024 (€104,347 Mil).

Regeneron Pharmaceuticals's annual market cap increased from Dec. 2021 (€62,249 Mil) to Dec. 2022 (€73,739 Mil) and increased from Dec. 2022 (€73,739 Mil) to Dec. 2023 (€87,644 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Regeneron Pharmaceuticals's Enterprise Value for Today is €69,961 Mil.


Regeneron Pharmaceuticals Market Cap Historical Data

The historical data trend for Regeneron Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Market Cap Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36,777.38 42,283.08 62,249.04 73,738.88 87,643.82

Regeneron Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84,986.86 87,643.82 98,285.91 107,650.75 104,346.87

Competitive Comparison of Regeneron Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Market Cap falls into.



Regeneron Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Regeneron Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=€801*109.418
=€87,644

Regeneron Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=€947.6*110.117
=€104,347

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regeneron Pharmaceuticals  (WBO:REGN) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Regeneron Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

From GuruFocus